Superbugs could kill a million Chinese a year: economist

Image
AFP Beijing
Last Updated : Mar 26 2015 | 9:07 PM IST
China faces a million deaths a year from antibiotic-resistant superbugs and a loss of USD 20 trillion by 2050, an economist and former top Goldman Sachs executive said today.
Beijing should "take ownership" of anti-microbial resistance (AMR) when it hosts the G20 summit next year, said Jim O'Neill, the leader of a British government-commissioned review on the subject.
"Here is an issue that doesn't distinguish between religion, colour, race," he said. "Whether you're Sunni or Shiite, you're going to get killed by AMR if we don't do something about it."
O'Neill, former chief economist at the US investment bank and chairman of Goldman Sachs Asset Management, said that the threat put "China's remarkable economic performance in the last decade and its enormous future potential" in jeopardy.
"Drug-resistant infections could cost the Chinese economy 20 trillion USD by 2050, and even more shockingly, cause an additional 1 million deaths per year," he said.
The review, announced last year by British Prime Minister David Cameron, has found that by 2050, drug-resistant infections could cut global gross domestic product by 2.0 to 3.5 per cent and kill 10 million people a year around the world.
In comparison the second-biggest killer, cancer, would account for about 8.2 million deaths a year by 2050, according to the review.
Several novel diseases have emerged from China in recent years, including Severe Acute Respiratory Syndrome (SARS) and human outbreaks of different strains of bird flu.
Beijing has come under criticism in the past for its state-run hospital system, in which medical institutions are heavily dependent on antibiotics sales for their revenue.
Experts say the system incentivises doctors to prescribe unnecessary antibiotics, thus exacerbating the problem of drug resistance.
O'Neill -- who is known for having coined the BRIC acronym to refer to emerging powers Brazil, Russia, India and China -- acknowledged the issue, telling reporters: "You've got to think of better ways of compensating the medical profession.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 26 2015 | 9:07 PM IST

Next Story